新活素在急性心肌梗死患者经皮冠状动脉介入治疗术后的应用价值

Application Value of Neoactive in Patients with Acute Myocardial Infarction after Percutaneous Coronary Intervention

目的 探讨新活素在急性心肌梗死患者经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)术后的应用价值。方法 方便选取2018年3月—2020年12月盐城市第一人民医院收治的62例急性心肌梗死患者为研究对象,随机分为观察组30例和对照组32例。观察组在PCI术后采用新活素(冻干重组人脑利钠肽)微量泵泵入24 h,并口服阿司匹林+氯吡格雷12个月。对照组仅在PCI术后采用阿司匹林+氯吡格雷治疗。比较两组治疗24 h后的心功能、随访1年的心血管不良事件、药物不良反应。结果 治疗24 h后,观察组的血清N末端B型脑钠肽水平为(120.54±37.55)pg/mL,低于对照组(148.30±42.54)pg/mL,差异有统计学意义(t=2.717,P=0.009);观察组的血清肌酸激酶同工酶水平为(16.94±4.23)U/L,低于对照组(20.25±4.69)U/L,差异有统计学意义(t=2.911,P=0.005)。随访1年后,观察组心血管不良事件总发生率10.00%低于对照组的31.25%,差异有统计学意义(χ^(2)=4.219,P=0.040)。观察组不良反应总发生率为26.67%,对照组为21.88%,差异无统计学意义(χ^(2)=0.194,P=0.660)。结论 急性心肌梗死患者PCI术后应用新活素治疗明显改善心功能,并且减少远期心血管不良事件,安全性尚可。

Objective To investigate the application value of neoactive in patients with acute myocardial infarction after percutaneous coronary intervention(PCI).Methods A total of sixty-two patients with acute myocardial infarction admitted to Yancheng First People's Hospital admitted from March 2018 to December 2020 were conveniently selected as the study objects,and randomly divided into observation group(30 cases)and control group(32 cases).The observation group was injected with neoactive(freeze-dried recombinant human brain natriuretic peptide)micropump for 24 h after PCI,and took aspirin+clopidogrel orally for 12 months.The control group was only treated with aspirin+clopidogrel after PCI.Cardiac function 24 h after treatment,cardiovascular adverse events and adverse drug reactions in the two groups were compared for 1 year.Results After 24 h of treatment,the level of N-terminal B-type brain natripeptide in the observation group was(120.54±37.55)pg/mL,lower than that in the control group(148.30±42.54)pg/mL,and the difference was statistically significant(t=2.717,P=0.009).The serum creatine kinase isoenzyme level in the observation group was(16.94±4.23)U/L,which was lower than that in the control group(20.25±4.69)U/L,and the difference was statistically significant(t=2.911,P=0.005).After 1 year of follow-up,the total incidence of cardiovascular adverse time in the observation group was 10.00%lower than 31.25%in the control group,and the difference was statistically significant(χ^(2)=4.219,P=0.040).Observation group the incidence of adverse reactions to the total was 26.67%,the control group was 21.88%,the difference was not statistically significant(χ^(2)=0.194,P=0.660).Conclusion In patients with acute myocardial infarction,neoactive therapy after PCI can significantly improve cardiac function and reduce long-term cardiovascular adverse events,with reasonable safety.